Table 3.
Treatment targets in MPZ-associated neuropathy
| Target | Mutation/model | Intervention | Reference |
|---|---|---|---|
| UPR pathway | S63del | CHOP ablation | Sharifov (2013) |
| GADD34 inhibition | D’Antonio (2013) | ||
| Salubrinol | Boyce (2005), D’Antonio (2013) | ||
| Sephin1 | Das (2015) | ||
| R98C | Curcumin derivatives | Patzko 2012 | |
| ERAD pathway | S63del | N-Acetyl-D-glucosamine (GlcNAc) | Volpi (2019) |
| Axonal neuregulin type III | S63del | Overexpression of Nrg1TIII | Scapin (2019) |
| Suppression of Nrg1TIII inhibitor (TACE/ADAM17) | Scapin (2019) | ||
| NaV1.8 sodium channels | MPZ-deficient mice | NaV1.8 blocker | Rosberg (2016) |
UPR unfolded protein response, CHOP CCAAT-enhancer-binding protein homologous protein, GADD34 growth arrest and DNA damage-inducible protein, SERCA sarcoplasmic/endoplasmic reticulum Ca2 + -ATPase, ERAD endoplasmic-reticulum-associated protein degradation, Nrg1TIII axonal neuregulin 1 type III, TACE tumor necrosis factor-α-converting enzyme, ADAM17 A disintegrin and metalloprotease 17, MPZ myelin protein zero